Advice

Efalizumab (Raptiva) for the treatment of moderate to severe chronic plaque psoriasis

In Feb 2009 the European Medicines Agency suspended the marketing authorisation for this product across the EU due to safety concerns.

The SMC Advice has been removed from the website.

Medicine details

Medicine name:
Efalizumab (Raptiva®)
SMC ID:
146/04
Indication:
Moderate to severe chronic plaque psoriasis
Pharmaceutical company
Serono Ltd
BNF chapter
Skin
Submission type
Full submission
Status
Withdrawn
Date advice published:
10 January 2005